Natural History and Response to Treatment of HCV Infection among Egyptian Survivors of Childhood Malignancy

Pediatric Hematology and Oncology

Volumn 32, Issue 2, 2015, Pages 138-145

  El Raziky, Mona Saeed ^a   Halawa, Eman Fawzy ^a   Draz, Iman Hassan ^a   Ali, Mona Samir ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b National Hepatology and Tropical Medicine Institute   (Egypt)

Author keywords

acute leukemias; infectious diseases; late effects; pediatrics; virology

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; LIVER ENZYME; PEGINTERFERON;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; EGYPTIAN; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS ELISA KIT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; PATIENT REFERRAL; PHYSICAL EXAMINATION; RISK FACTOR; TREATMENT RESPONSE; ULTRASOUND TRANSDUCER; EGYPT; HEPACIVIRUS; NEOPLASMS; PRESCHOOL CHILD; SURVIVOR;

ADOLESCENT; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; EGYPT; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; NEOPLASMS; RISK FACTORS; SURVIVORS;

EID: 84938680684     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2014.958885     Document Type: Article

References (21)

1. Kebudi R, Ayan I, Ýlmaz G, et al. Seroprevalence of hepatitis B, hepatitis C and immunodeficiency virus infections in children with cancer at diagnosis and following therapy in Turkey. Med Pediatr Oncol. 2000;34:102-105.
2. Mostafa A, Ebeid E,Mansour T, et al. Seroprevalence of hepatitis B and C in pediatricmalignancies. J Egyptian Nat. Cancer Inst. 2003;15:33-42.
3. Mohan N,Gonzalez-PeraltaR, FujisawaT, et al. ChronichepatitisCvirus infection in children. JPGN. 2010;50:123-131.
4. El-SayedMH,Mohamed MM, KarimA, et al. Severe liver disease is caused by HBV rather than HCV in children with hematologicalmalignancies. Hematol J. 2003;4(5):321-327.
5. Wirth S, Kelly D, Sokal E, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2011;52(2):233-237.
6. Cesaro S, Bortolotti F, Petris MG, et al. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer. 2010;55:108-112.
7. KnodellRG, IshakKG,Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
8. Cesaro S, PetrisMG, Rossetti F, et al. Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood. 1997;90:1315-1320.
9. Sharaf-Eldeen S, Salama K, Eldemerdash S, Hassan HM. Hepatitis B and C viruses in Egyptian children withmalignancy. J Med Sci. 2007;7:1003-1008.
10. Kose S, Olmezoglu A, Gozaydin A, Ece G. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr. 2011;29:652-655.
11. Strickland DK, Riely CA, Patrick CC, et al. Hepatitis C infection among survivors of childhood cancer. Blood. 2000;95:3065-3070.
12. Castellino S, Lensing S, Riely C, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude children's research hospital hepatitis C seropositive cohort. Blood. 2004;103:2460-2466.
13. El-Raziky MS, El-HawaryM, El-KoofyN, et al. Hepatitis C virus infection in Egyptian children: single centre experience. J Viral Hepat. 2004;11:471-476.
14. Paul IM, Sanders J,Ruggiero F, et al. ChronichepatitisCvirus infections inleukemia survivors: prevalence, viral load, and severity of liver disease. Blood. 1999;93:3672-3677.
15. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood Leukemia. Blood. 1997;90:4628-4633.
16. Esmat G, Hashem M, El-Raziky M, et al. Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int. 2012;32:449-456.
17. Locasciulli A, Cavalletto D, Pontisso P, et al. Hepatitis C virus serum markers and liver disease in children with leukemia during and after chemotherapy. Blood. 1993;82:2564-2567.
18. Fioredda F, Moser A, Bertoluzzo L, et al. Natural course of HCV infection in childhood cancer survivors. Support Care Cancer. 2010;18:1413-1420.
19. Lo Nigro L, la spina M,Mirabile E, et al. Use of peg-interferon alfa 2-a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL. Pediatr Blood Cancer. 2004;4:185.
20. Ghaffar TY, El Naghy S, El Sebaie H, et al. Pegylated interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr. 2009;76:895-898.
21. El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, et al. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol. 2014;20(16):4681-4691.